867 research outputs found
A Systematic Review of Music Therapy Practice and Outcomes with Acute Adult Psychiatric In-Patients
PMCID: PMC3732280This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Intergenerational change and familial aggregation of body mass index
The relationship between parental BMI and that of their adult offspring, when increased adiposity can become a clinical issue, is unknown. We investigated the intergenerational change in body mass index (BMI) distribution, and examined the sex-specific relationship
between parental and adult offspring BMI. Intergenerational
change in the distribution of adjusted BMI in 1,443
complete families (both parents and at least one offspring)
with 2,286 offspring (1,263 daughters and 1,023 sons) from
the west of Scotland, UK, was investigated using quantile
regression. Familial correlations were estimated from
linear mixed effects regression models. The distribution
of BMI showed little intergenerational change in the normal
range (\25 kg/m2), decreasing overweightness (25–
\30 kg/m2) and increasing obesity (C30 kg/m2). Median
BMI was static across generations in males and decreased
in females by 0.4 (95% CI: 0.0, 0.7) kg/m2; the 95th percentileincreased by 2.2 (1.1, 3.2) kg/m2 in males and 2.7
(1.4, 3.9) kg/m2 in females. Mothers’ BMI was more
strongly associated with daughters’ BMI than was fathers’
(correlation coefficient (95% CI): mothers 0.31 (0.27,
0.36), fathers 0.19 (0.14, 0.25); P = 0.001). Mothers’ and
fathers’ BMI were equally correlated with sons’ BMI
(correlation coefficient: mothers 0.28 (0.22, 0.33), fathers
0.27 (0.22, 0.33). The increase in BMI between generations
was concentrated at the upper end of the distribution. This,
alongside the strong parent-offspring correlation, suggests that the increase in BMI is disproportionally greater among
offspring of heavier parents. Familial influences on BMI among middle-aged women appear significantly stronger from mothers than father
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
The phase III AZA-001 study established that azacitidine significantly improves overall survival compared with conventional care regimens (hazard ratio 0.58 [95% confidence interval 0.43–0.77], P<0.001). This analysis was conducted to investigate the relationship between treatment response and overall survival. AZA-001 data were analyzed in a multivariate Cox regression analysis with response as a time-varying covariate. Response categories were “Overall Response” (defined as complete remission, partial remission, or any hematologic improvement) and “Stable Disease” (no complete or partial remission, hematologic improvement, or progression) or “Other” (e.g. disease progression). Achieving an Overall Response with azacitidine reduced risk of death by 95% compared with achieving an Overall Response with the conventional care regimens (hazard ratio 0.05 [95%CI: 0.01–0.43], P=0.006). Sensitivity analyses indicated that significantly improved overall survival remained manifest for patients with a hematologic improvement who had never achieved complete or partial remission (hazard ratio 0.19 [95%CI: 0.08–0.46], P<0.001). Stable Disease in both azacitidine-treated and conventional care-treated patients was also associated with a significantly reduced risk of death (hazard ratio 0.09, [95%CI: 0.06–0.15]; P<0.001). These results demonstrate azacitidine benefit on overall survival compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes who achieve hematologic response but never attain complete or partial remission, in addition to the survival advantage conferred by achievement of complete or partial remission. This study was registered with clinicaltrials.gov (NCT00071799)
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a relationship between complete remission (CR) and survival, is increasingly being questioned (Cheson (2006) Blood 108 419). Results of AZA-001 show CR is sufficient but not necessary to prolong OS (List (2008) Clin Oncol 26 7006). Indeed, the AZA CR rate in AZA-001 was modest (17%), while partial remission (PR, 12%) and haematological improvement (HI, 49%) were also predictive of prolonged survival. This analysis was conducted to assess the median number of AZA treatment cycles associated with achievement of first response, as measured by IWG 2000-defined CR, PR or HI (major + minor). The number of treatment cycles from first response to best response was also measured
Evidences for a quasi 60-year North Atlantic Oscillation since 1700 and its meaning for global climate change
The North Atlantic Oscillation (NAO) obtained using instrumental and
documentary proxy predictors from Eurasia is found to be characterized by a
quasi 60-year dominant oscillation since 1650. This pattern emerges clearly
once the NAO record is time integrated to stress its comparison with the
temperature record. The integrated NAO (INAO) is found to well correlate with
the length of the day (since 1650) and the global surface sea temperature
record HadSST2 and HadSST3 (since 1850). These findings suggest that INAO can
be used as a good proxy for global climate change, and that a 60-year cycle
exists in the global climate since at least 1700. Finally, the INAO ~60-year
oscillation well correlates with the ~60- year oscillations found in the
historical European aurora record since 1700, which suggests that this 60-year
dominant climatic cycle has a solar-astronomical origin
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update
Azacitidine (AZA), as demonstrated in the phase III trial (AZA-001), is the first MDS treatment to significantly prolong overall survival (OS) in higher risk MDS pts ((2007) Blood 110 817). Approximately, one-third of the patients (pts) enrolled in AZA-001 were FAB RAEB-T (≥20–30% blasts) and now meet the WHO criteria for acute myeloid leukaemia (AML) ((1999) Blood 17 3835). Considering the poor prognosis (median survival <1 year) and the poor response to chemotherapy in these pts, this sub-group analysis evaluated the effects of AZA versus conventional care regimens (CCR) on OS and on response rates in pts with WHO AML
Compliance and persistence with osteoporosis medications: A critical review of the literature
It is widely acknowledged that compliance and persistence with oral osteoporosis medications, particularly with bisphosphonates, is poor. Several excellent reviews have been written on compliance and persistence with osteoporosis medications and have discussed improvements seen with extended dosing intervals. This review begins with studies on extended dosing intervals to examine the limitations of administrative claims data. It also looks at compliance and persistence across multiple medical conditions, examining the importance of prescription fulfillment, intentional choice, causation and possible interventions
Constraints on the Progenitor System of the Type Ia Supernova SN 2011fe/PTF11kly
Type Ia supernovae (SNe) serve as a fundamental pillar of modern cosmology,
owing to their large luminosity and a well-defined relationship between
light-curve shape and peak brightness. The precision distance measurements
enabled by SNe Ia first revealed the accelerating expansion of the universe,
now widely believed (though hardly understood) to require the presence of a
mysterious "dark" energy. General consensus holds that Type Ia SNe result from
thermonuclear explosions of a white dwarf (WD) in a binary system; however,
little is known of the precise nature of the companion star and the physical
properties of the progenitor system. Here we make use of extensive historical
imaging obtained at the location of SN 2011fe/PTF11kly, the closest SN Ia
discovered in the digital imaging era, to constrain the visible-light
luminosity of the progenitor to be 10-100 times fainter than previous limits on
other SN Ia progenitors. This directly rules out luminous red giants and the
vast majority of helium stars as the mass-donating companion to the exploding
white dwarf. Any evolved red companion must have been born with mass less than
3.5 times the mass of the Sun. These observations favour a scenario where the
exploding WD of SN 2011fe/PTF11kly, accreted matter either from another WD, or
by Roche-lobe overflow from a subgiant or main-sequence companion star.Comment: 22 pages, 6 figures, submitte
Identification and functional characterisation of CRK12:CYC9, a novel cyclin-dependent kinase (CDK)-cyclin complex in Trypanosoma brucei
The protozoan parasite, Trypanosoma brucei, is spread by the tsetse fly and causes trypanosomiasis in humans and animals. Both the life cycle and cell cycle of the parasite are complex. Trypanosomes have eleven cdc2-related kinases (CRKs) and ten cyclins, an unusually large number for a single celled organism. To date, relatively little is known about the function of many of the CRKs and cyclins, and only CRK3 has previously been shown to be cyclin-dependent in vivo. Here we report the identification of a previously uncharacterised CRK:cyclin complex between CRK12 and the putative transcriptional cyclin, CYC9. CRK12:CYC9 interact to form an active protein kinase complex in procyclic and bloodstream T. brucei. Both CRK12 and CYC9 are essential for the proliferation of bloodstream trypanosomes in vitro, and we show that CRK12 is also essential for survival of T. brucei in a mouse model, providing genetic validation of CRK12:CYC9 as a novel drug target for trypanosomiasis. Further, functional characterisation of CRK12 and CYC9 using RNA interference reveals roles for these proteins in endocytosis and cytokinesis, respectively
- …